Cencora (NYSE:COR) 주식

Cencora

Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

CoreSite Realty

FedEx planes.

Large Cap

News

Movers

Trading Ideas

ASND

BMRN

BNTX

CHWY

KSPI

MUSA

RIVN

SMMT

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 서밋 테라퓨틱스(NASDAQ:SMMT)의 주식이 23.61% 하락했다. 이 회사는 새롭고 잠재적인 최초의 연구용 이중특이성 항체인 아이보네스시맙(ivonescimab)에 대한 데이터가 2024년 ESMO 연례 회의에서 발표되었다고 발표했다.

노보 노디스크, 츄이 및 페덱스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 15일-9월 21일)

yoga LULU Lululemon

Equities

BEKE

BGNE

LULU

MSTR

NDSN

지난주 이들 10개 대형주는 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 내셔널 그리드 트랜스코(NYSE:NGG)가 70억 파운드의 자본금을 늘리고 연간 매출 결과가 전년 대비 감소했다고 보고한 후 주각가 17.1% 급락했다. 

지난주 최악의 성과를 보인 룰루레몬 애틀라티카 포함 10개의 대형주 (5월 19일-5월 26일)

Cencora Inc

Coreto

GLOBAL CORD BLOOD CORP by Global Cord Blood Corporation

Global Cord Blood Corp

CORNWALL RESOURCES INC by Cornwall Resources, Inc.

cVault.finance

Core - United States Dollar

Coreum - United States Dollar

Cordia Corp

CorEnergy Infrastructure Trust Inc Depositary Shares each representing 1/100th of a whole share of Series A Preferred Stock

Teucrium Corn Fund ETV

iShares International Country Rotation Active ETF

Pimco Investment Grade Corporate Bond Index Exchange-Traded Fund

CorEnergy Infrastructure Trust Inc OM

CorEnergy Infrastructure Trust Inc

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics Inc

Volatility Shares Trust 2x Corn ETF

Core Scientific Inc

Core Scientific Inc Ordinary Shares - Class A

Core Scientific, Inc. - Tranche 1 Warrants

Core Scientific, Inc. - Tranche 2 Warrants

The portfolio manager of AdvisorShares Focused Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWS#NYSE">CWS</a>) shares why his company's ETF is outperforming the market and many other<a href="https://www.benzinga.com/etfs"> ETFs in 2025.</a>
Beating the Market: AdvisorShares Portfolio Strategist Eddy Elfenbein highlighted the ETF he runs that beat the market in 2025 during an exclusive interview with Benzinga at Future Proof Citywide.
"We're beating the market this year," Elfenbein told Benzinga. He said it helps that the market has been "nervous" this year, pushing the nine-year-old ETF to have a five-star Morningstar rating.
"We have a lot of conservative stocks."
Elfenbein said that's where investors want to be right now and that the ETF is "at the right place at the right time."
The AdvisorShares Focused Equity ETF often holds around 25 stocks. Here are the current top five holdings and the percentage of assets they make up.
<ul>
<li>Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>): 4.8%</li>
<li>Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>): 4.7%</li>
<li>Rollins Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>): 4.5%</li>
<li>American Water Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>): 4.5%</li>
<li>Heico Crop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>): 4.4%</li>
</ul>
The portfolio manager told Benzinga that the goal of the ETF was to follow the market and create a product that puts investors first. Elfenbein said the ETF has low turnover, is tax efficient, and focuses on transparency.
Read Also: <a href="https://www.benzinga.com/news/events/25/03/44520918/andrew-pitcairn-on-multi-generational-wealth-think-in-50-year-increments">Andrew Pitcairn On Multi-Generational Wealth: &#8216;Think In 50-Year Increments&#8217;</a>
Advice for Investors: With the stock market experiencing high volatility in 2025, Elfenbein provided some advice for investors during the interview.
"The most important thing to have as an investor is a long-term focus," Elfenbein said.
The portfolio manager said the market has experienced a recent 10% pullback from the highs, which sounds bad but is less than the annual average one-year pullback of 14% each year from top to bottom.
"The key is riding those out, not letting your emotions get the best of you."
Elfenbein said it's important not to panic and head for the exits as investors because of some volatility. "Keep a level head and have good stocks that will weather the storm."
Price Action: The AdvisorShares Focused Equity ETF is up 1.8% year-to-date in 2025, beating the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which is down 2.8% year-to-date in 2025.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/events/25/03/44497987/xtrackers-etfs-offer-unique-exposure-to-hottest-themes-in-market-the-internet-era-times-two">Xtrackers ETFs Offer Unique Exposure To Hottest Themes In Market: &#8216;The Internet Era Times Two&#8217;</a></li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
 <iframe loading="lazy" title="AdvisorShares &#x7C; Future Proof CityWide Miami 2025" width="500" height="281" src="https://www.youtube.com/embed/Hj0iYr31PoU?list=PL_xynMYmeEycXKNjPWkI98N6vKR-7s4D0" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Photo: Shutterstock

Exclusives

Interview

ETFs

EXCLUSIVE: AdvisorShares Portfolio Manager Says Market 'Nervous' In 2025, Encourages Investors To Have 'Long-Term Focus'

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 10 years by 7.55% on an annualized basis producing an average annual return of 18.31%. Currently, Cencora has a market capitalization of $52.20 billion. 
Buying $1000 In COR: If an investor had bought $1000 of COR stock 10 years ago, it would be worth $5,371.18 today based on a price of $269.48 for COR at the time of writing.
<h3>Cencora's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742998508_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cencora Stock In The Last 10 Years

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $276.5, along with a high estimate of $301.00 and a low estimate of $251.00. This current average reflects an increase of 5.64% from the previous average price target of $261.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1741986021_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Cencora is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$274.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>John Belton</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$251.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$301.00</td>
<td>$289.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cencora. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cencora compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Cencora's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cencora analyst ratings.</a>
<h2>About Cencora</h2>
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
<h3>A Deep Dive into Cencora's Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Cencora's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 12.78% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Cencora's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.6% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 112.0%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Cencora's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.72% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Cencora's debt-to-equity ratio stands notably higher than the industry average, reaching 35.96. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What Analysts Are Saying About Cencora Stock

Wells Fargo analyst Stephen Baxter maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Equal-Weight and raises the price target from $251 to $274.

Price Target

Wells Fargo Maintains Equal-Weight on Cencora, Raises Price Target to $274

This updated guidance reflects the Company's continued momentum in the second quarter of fiscal 2025 for its core U.S. Healthcare Solutions reportable segment and does not reflect any change in expectations for its recently completed acquisition of Retina Consultants of America.

Earnings

Guidance

Health Care

General

Cencora Expects 2025 Adjusted EPS Of $15.30-$15.60, Up From The Previous Range Of $15.25-$15.55 Compared To Consensus Of $16.82-8K

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 5 years by 8.2% on an annualized basis producing an average annual return of 20.8%. Currently, Cencora has a market capitalization of $47.04 billion. 
Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $257.27 today based on a price of $242.63 for COR at the time of writing.
<h3>Cencora's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739572215_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$75.00</td>
<td>$39.4K</td>
<td>2.1K</td>
<td>8.1K</td>
</tr>
<tr>
<td>AHCO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$10.00</td>
<td>$71.4K</td>
<td>0</td>
<td>4.7K</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$145.00</td>
<td>$105.8K</td>
<td>1.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>COR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$230.00</td>
<td>$822.5K</td>
<td>495</td>
<td>258</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$35.00</td>
<td>$81.1K</td>
<td>5.1K</td>
<td>217</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$270.00</td>
<td>$140.0K</td>
<td>355</td>
<td>200</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$390.00</td>
<td>$39.6K</td>
<td>484</td>
<td>151</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$610.00</td>
<td>$53.0K</td>
<td>100</td>
<td>137</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$67.50</td>
<td>$33.6K</td>
<td>1.8K</td>
<td>120</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$860.00</td>
<td>$25.3K</td>
<td>50</td>
<td>112</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 3 day(s) on February 14, 2025. This event was a transfer of 200 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $39.4K, with a price of $197.0 per contract. There were 2192 open contracts at this strike prior to today, and today 8123 contract(s) were bought and sold. 
• Regarding AHCO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>), we observe a put option sweep with bearish sentiment. It expires in 220 day(s) on September 19, 2025. Parties traded 476 contract(s) at a $10.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $71.4K, with a price of $150.0 per contract. There were 0 open contracts at this strike prior to today, and today 4752 contract(s) were bought and sold. 
• For THC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), we notice a call option sweep that happens to be neutral, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 300 contract(s) at a $145.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $105.8K, with a price of $355.0 per contract. There were 1108 open contracts at this strike prior to today, and today 1040 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a call option trade with bearish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 250 contract(s) at a $230.00 strike. The total cost received by the writing party (or parties) was $822.5K, with a price of $3290.0 per contract. There were 495 open contracts at this strike prior to today, and today 258 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bullish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 100 contract(s) at a $35.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $81.1K, with a price of $812.0 per contract. There were 5109 open contracts at this strike prior to today, and today 217 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a put option trade that happens to be bullish, expiring in 129 day(s) on June 20, 2025. This event was a transfer of 200 contract(s) at a $270.00 strike. The total cost received by the writing party (or parties) was $140.0K, with a price of $700.0 per contract. There were 355 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 99 contract(s) at a $390.00 strike. This particular put needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $39.6K, with a price of $400.0 per contract. There were 484 open contracts at this strike prior to today, and today 151 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a call option sweep that happens to be bullish, expiring in 17 day(s) on February 28, 2025. This event was a transfer of 53 contract(s) at a $610.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $53.0K, with a price of $1000.0 per contract. There were 100 open contracts at this strike prior to today, and today 137 contract(s) were bought and sold. 
• Regarding AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we observe a call option sweep with bearish sentiment. It expires in 65 day(s) on April 17, 2025. Parties traded 57 contract(s) at a $67.50 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $33.6K, with a price of $590.0 per contract. There were 1841 open contracts at this strike prior to today, and today 120 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option trade that happens to be bearish, expiring in 157 day(s) on July 18, 2025. This event was a transfer of 4 contract(s) at a $860.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $6340.0 per contract. There were 50 open contracts at this strike prior to today, and today 112 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AHCO

AMGN

MRNA

10 Health Care Stocks With Whale Alerts In Today's Session

Health insurance company Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) is set to release its fourth-quarter 2024 earnings report on Feb. 11, before market hours. The stock has dropped 2.37% from the previous close, as of writing, on Feb.10, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. 
The stock is up 5.58% year-to-date but has fallen 27.73% in the past year.
In the previous quarter, Humana reported revenues of $29.4 billion — a 15.2% year-over-year increase. It surpassed analysts&#8217; expectations by 2.6%. 
The company also achieved a solid beat on earnings per share (EPS) estimates, though it slightly missed full-year EPS guidance estimates.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/02/43600652/super-micro-computer-q2-earnings-preview-accounting-updates-nasdaq-deadline-on-watch">Super Micro Computer Q2 Earnings Preview: Accounting Updates, Nasdaq Deadline On Watch</a>
What To Watch: For the upcoming report, analysts anticipate a 12% year-over-year revenue growth to $28.83 billion. This indicates a deceleration from the 14.7% growth observed in the same quarter last year. An adjusted loss of $2.12 per share is expected.
It&#8217;s noteworthy that some of Humana&#8217;s peers in the health insurance sector have already reported their Q4 results. Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) delivered a 3.4% year-over-year revenue growth, beating analysts&#8217; expectations by 4.4%, while Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) reported a 12.8% increase, topping estimates by 5.2%. 
Investors will be keen to see if Humana can maintain its growth trajectory and how its performance compares to industry peers. Additionally, any updates on operating cost ratios will be closely monitored, especially after the company projected a 30 basis point decrease in its adjusted operating cost ratio for the year during the Q3 earnings call.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43604305/what-to-expect-when-biotech-giant-gilead-reports-q4-earnings-on-tuesday">What To Expect When Biotech Giant Gilead Reports Q4 Earnings On Tuesday?</a></li>
</ul>
Photo: Shutterstock<a href="https://press.humana.com/news/news-details/2025/Humana-Inc.-to-Release-Fourth-Quarter-2024-Results-on-February-11-2025/default.aspx?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener"></a>

Previews

Humana Earnings On Deck: Investors Brace For Slower Growth Clip

On Thursday, Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) reached an agreement for the early settlement of certain prepaid variable share forward transactions related to shares of Cencora, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>).
As part of the early settlement, Walgreens Boots will transfer approximately 6.1 million Cencora shares to the financial institutions and make a net cash payment of about $20 million.
Alongside this, the company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The company receives approximately&nbsp;$300 million&nbsp;from the early settlement and the concurrent sale of shares.
Following this settlement, WBA retains 12.6 million Cencora shares under remaining prepaid contracts, set to mature primarily in March, June, and September 2025, with the potential for additional cash proceeds.
The proceeds will primarily be used for debt reduction and general corporate purposes.&nbsp;&nbsp;The transactions were scheduled to mature in March and June 2026.
By settling early and executing a concurrent share sale, WBA is realizing the embedded cash value of the prepaid variable share forwards. With this settlement, Walgreens has lowered its stake in Cencora from 10% to 6%.
Notably, Walgreens has been cutting its stake in Concera for the last few years, decreasing the stake from 12% to 10% for around <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40119033/walgreens-boots-alliance-sells-shares-of-cencora-for-approximately-1-1-billion-of-proceeds" rel="noreferrer noopener">$1.1 billion in August 2024</a>.
Also, in May 2024,&nbsp;Walgreens reduced ownership of Cencora shares from 13% to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38975615/walgreens-boots-alliance-sells-shares-of-cencora-for-400-million-of-proceeds" rel="noreferrer noopener">12% for approximately $400 million</a>.
These transactions, along with other recent measures such as the dividend suspension, further strengthen WBA&#8217;s ability to address its upcoming debt maturities in fiscal 2026.
Last month, the company announced it is halting its quarterly dividend while the management team reviews and adjusts its capital allocation strategy to match the company&#8217;s <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/43397182/whats-going-on-with-walgreens-shares-friday-2" rel="noreferrer noopener">broader long-term recovery efforts</a>.
Investors can gain exposure to the stock via Invesco High Yield Equity Dividend Achievers ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEY#NASDAQ">PEY</a>) and Invesco S&amp;P 500 Equal Weight Consumer Staples ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSPS#NYSE">RSPS</a>).
Price Action: WBA shares are up 0.40% at $10.09 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43390001/feds-favorite-inflation-gauge-rises-as-predicted-consumer-spending-jumps-at-fastest-pace-in-9-months" target="_blank" rel="noreferrer noopener">Fed&#8217;s Favorite Inflation Gauge Rises As Predicted, Consumer Spending Jumps At Fastest Pace In 9 Months</a></li>
</ul>
Image via Shutterstock.

Mid Cap

RSPS

Walgreens Cashes In: Slashes Cencora Stake Again In Debt-Fighting Move

Transaction Highlights
<ul>
<li>Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares</li>
<li>Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares</li>
<li>Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional cash proceeds at maturity. These remaining prepaid variable share forward contracts are mainly scheduled to mature during March, June and September of calendar year 2025.</li>
<li>Use of proceeds will primarily be for debt paydown, as the Company proactively seeks to address its debt maturities in fiscal year 2026, and for general corporate purposes</li>
</ul>

Reported Earlier, Walgreens Boots Alliance Secures $300M Through Early Settlement Of Prepaid Variable Share Forward Contracts On Cencora

Evercore ISI Group analyst John Belton maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Outperform and raises the price target from $270 to $280.

Evercore ISI Group Maintains Outperform on Cencora, Raises Price Target to $280

Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from <a href="https://www.benzinga.com/25/02/43494246/private-employment-rises-by-183000-beats-estimates-in-january-consumer-facing-industries-drove-hiring">positive labor market data.</a>
The S&amp;P 500 gained 0.3% to 6,045 points, while the Dow Jones Industrial Average rose 0.6%, now trading less than 1% below its all-time high.
Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) missed quarterly earnings expectations on its cloud business, triggering a 7% drop, its worst single-day decline in a year. On the upside, Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) surged 6% after beating estimates, fueling a rally in chip stocks. Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) also gained 3.4%.
The Russell 2000 outperformed with a 0.9% gain, reflecting strength in smaller-cap stocks.
Fresh labor market data signaled resilience. Private sector employment rose by 183,000 in January according to the ADP report, surpassing expectations of 150,000. The services sector continued expanding,<a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43499292/us-services-growth-slows-in-january-as-tariff-concerns-mount"> as per ISM survey</a>, though at a slightly slower-than-anticipated pace.
Investors piled into Treasuries, sending yields tumbling across the curve. The 30-year yield fell to its lowest level since Dec. 18, 2024, while the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) rallied 1.9%.
Gold extended its bull run, surging over 1% to a record $2,870 per ounce, driven by continued central bank buying. Copper jumped 2%. 
In crypto markets, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) edged down 1.2% to $97,000. 
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>• Russell 2000</td>
<td>2,310.94</td>
<td>0.9%</td>
</tr>
<tr>
<td>• Dow Jones</td>
<td>44,801.97</td>
<td>0.6%</td>
</tr>
<tr>
<td>• S&amp;P 500</td>
<td>6,054.99</td>
<td>0.3%</td>
</tr>
<tr>
<td>• Nasdaq 100</td>
<td>21,621.68</td>
<td>0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 2:00 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;rose 0.3% to $602.97.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.5% to $447.60.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;inched 0.2% up to $525.63.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 1% to $229.09.</li>
<li>The&nbsp;Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up 1.6%; the&nbsp;Communication Services Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) lagged, down 1.2%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
Stocks reacting on earnings reports included: 
<ul>
<li>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>): up 5.9%</li>
<li>Chipotle Mexican Grill Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>): down 2.4%</li>
<li>Mondelez International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>): up 0.62%</li>
<li>Simon Property Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>): 3.55%</li>
<li>Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>): up 5.7%</li>
<li>Snap Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NASDAQ">SNAP</a>): down 6.55%</li>
<li>IDEX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>): down 9.61%</li>
<li>Walt Disney Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>): down 1.77%</li>
<li>Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>): down 7.31%</li>
<li>Fiserv Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>): up 7.48%</li>
<li>Boston Scientific Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>): up 1.87%</li>
<li>Illinois Tool Works Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>): down 0.62%</li>
<li>Emerson Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>): down 2.61%</li>
<li>T. Rowe Price Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>): down 3.91%</li>
<li>Cencora Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>): up 0.83%</li>
<li>CDW Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>): up 4.54%</li>
<li>Ares Management Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>): down 2.51%</li>
<li>Bunge Global SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>): down 5.05%</li>
<li>Johnson Controls International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>): up 12.49%</li>
<li>Old Dominion Freight Line Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>): up 5.60%</li>
<li>Stanley Black &amp; Decker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>): down 1.43%</li>
<li>Ares Capital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>): down 3.26%</li>
<li>Criteo SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>): up 17.73%</li>
<li>Timken Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKR#NYSE">TKR</a>): up 2.86%</li>
<li>Performance Food Group Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>): down 1.91%</li>
<li>New York Times Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYT#NYSE">NYT</a>): down 11.56%</li>
<li>Griffon Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFF#NYSE">GFF</a>): up 9.00%</li>
<li>Harley-Davidson Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOG#NYSE">HOG</a>): down 0.63%</li>
<li>Capri Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>): down 13.94%</li>
<li>Azenta Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZTA#NASDAQ">AZTA</a>): up 1.04%</li>
<li>Vishay Intertechnology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSH#NYSE">VSH</a>): up 8.65%</li>
<li>Spire Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>): up 0.82%</li>
</ul>
Large-cap stocks slated to report earnings after the close are Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), McKesson Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), O&#8217;Reilly Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>), MetLife Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>), Cognizant Technology Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>), Corteva Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>), Allstate Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>), Skyworks Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>), Aflac Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>), Align Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>). 
Read now: 
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43503385/trumps-gaza-plan-for-seaside-resort-faces-global-pushback">Trump&#8217;s Plan To Turn Gaza Into Seaside Resort, Remove 2 Million Palestinians Roundly Rejected By World Leaders</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Tech

$BTC

ALGN

ARCC

ARES

AVGO

AZTA

CMRE

CPRI

CRTO

CTSH

CTVA

SPDR Dow Jones Industrial Average ETF Trust

GOOGL

MDLZ

NVDA

ODFL

ORLY

PFGC

QCOM

REYN

RSVR

SNAP

SWKS

TECH

iShares Trust Barclays 20+ Year Treasury Bond Fund

TROW

UBER

XLRE

Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday?

On Wednesday,&nbsp;Cencora, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) reported first-quarter 2025 sales increased 12.8% to $81.5 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $78.38 billion</a>.&nbsp;&nbsp;
The sales jump reflects a 13.6% increase in revenue within the U.S. Healthcare Solutions segment of $74 billion due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class and increased sales of specialty products to physician practices and health systems.&nbsp;
The company reported adjusted EPS of $3.73, up 13.7% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43489716/cencora-reports-fiscal-2025-first-quarter-results" rel="noreferrer noopener">consensus of $3.50</a>.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41780082/cencora-acquires-retina-care-practice-network-for-4-6-billion-boosts-dividend-on-better-than-expect" rel="noreferrer noopener">Cencora Acquires Retina Care Practice Network For $4.6 Billion, Boosts Dividend On Better Than Expected Q4 Earnings</a>
Adjusted gross profit in the first quarter of fiscal 2025 was $2.5 billion, a 6.1% increase compared to the same period in the previous fiscal year due to the increase in gross profit in both reportable segments.
Adjusted gross profit as a percentage of revenue was 3.11% in the fiscal 2025 first quarter, a decrease of 20 basis points from the prior year quarter due to the decline in U.S. Healthcare Solutions gross profit margin primarily due to increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, which have lower gross profit margins, lower COVID-19 vaccine sales and a lack of exclusive COVID-19 therapy sales, which have higher gross profit margins.
In the first quarter of fiscal 2025, adjusted operating income was $949.3 million, a 7.2% increase compared to the same period in the prior fiscal year, driven by a 9.9% increase in the U.S. Healthcare Solutions segment, partially offset by a 2.9% decrease in the International Healthcare Solutions segment.
Guidance:&nbsp;Cencora expects adjusted diluted EPS of $15.25 to $15.55, up from the previous range of $15.15 to $15.45 provided on January 2 and the initial guidance range of $14.80 to $15.10 and consensus of $15.28.
Revenue growth in 2025 is expected to be 8%-10% compared to prior guidance of 7%-9%.
<ul>
<li>U.S. Healthcare Solutions revenue growth is expected to be 9%-11%, up from a previous range of 7%-9%.</li>
<li>International Healthcare Solutions revenue growth to be 4%-5%, from the previous range of 7%-9%.</li>
</ul>
Price Action: COR stock is down 0.88% at $279.35 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43496003/aurora-cannabis-stock-jumps-on-record-breaking-q3-earnings" target="_blank" rel="noreferrer noopener">Aurora Cannabis Stock Jumps On &#8216;Record-Breaking&#8217; Q3 Earnings</a></li>
</ul>
Photo via Company

Cencora Q1 Earnings: Revenue And EPS Beat On Strong Push From Obesity Drugs, Specialty Medicines

Cencora Expects 2025 Revenue Growth Of 8%-10%, From The Previous Range Of 7%-9%

Fiscal Year 2025 Expectations on an Adjusted (non-GAAP) Basis
On January 2, 2025, Cencora updated its fiscal year 2025 financial guidance only for adjusted diluted EPS following the closing of the RCA acquisition to reflect the expected contribution from RCA and momentum in the U.S. Healthcare Solutions reportable segment.
Cencora is now updating its fiscal year 2025 adjusted diluted EPS guidance to better reflect the continued momentum in the U.S. Healthcare Solutions reportable segment. Additionally, the Company is updating its fiscal year 2025 financial guidance expectations for revenue, operating income and net interest expense to reflect the impact of the RCA acquisition and the continued momentum in the U.S. Healthcare Solutions segment. The Company now expects:
<ul>
<li>Revenue growth to be in the range of 8 to 10 percent, from the previous range of 7 to 9 percent;
<ul>
<li>U.S. Healthcare Solutions revenue growth to be in the range of 9 to 11 percent, from the previous range of 7 to 9 percent;</li>
<li>International Healthcare Solutions revenue growth to be in the range of 4 to 5 percent, from the previous range of 7 to 9 percent;</li>
</ul>
</li>
<li>Adjusted diluted EPS to be in the range of $15.25 to $15.55, up from the previous range of $15.15 to $15.45 provided on January 2, 2025 and the initial guidance range of $14.80 to $15.10.</li>
</ul>
Additional expectations now include:
<ul>
<li>Adjusted consolidated operating income growth to be in the range of 11.5 to 13.5 percent, from the previous range of 5 to 6.5 percent;
<ul>
<li>U.S. Healthcare Solutions segment operating income growth to be in the range of 14.5 to 16.5 percent, from the previous range of 5 to 6.5 percent;</li>
<li>International Healthcare Solutions segment as reported operating income growth to be flat, from the previous range of 5 to 6.5 percent;
<ul>
<li>On a constant currency basis, International Healthcare Solutions segment operating income growth to be approximately 5 percent;</li>
</ul>
</li>
</ul>
</li>
<li>Net interest expense to be in the range of $290 million to $310 million, from the previous range of $150 million to $170 million; and</li>
<li>Weighted average diluted shares outstanding is expected to be under 196 million, from the previous expectation of approximately 196 million.</li>
</ul>

Cencora Expects 2025 Adjusted EPS Of 15.25-$15.55 Versus Prior Guidance Of $15.15-$15.45 And Consensus of $15.28.

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) reported quarterly earnings of $3.73 per share which beat the analyst consensus estimate of $3.50 by 6.57 percent. This is a 13.72 percent increase over earnings of $3.28 per share from the same period last year. The company reported quarterly sales of $81.49 billion which beat the analyst consensus estimate of $78.38 billion by 3.96 percent. This is a 12.78 percent increase over sales of $72.25 billion the same period last year.

Cencora Q1 2025 Adj EPS $3.73 Beats $3.50 Estimate, Sales $81.49B Beat $78.38B Estimate

AMSC

AOSL

APPS

ARAY

ASGN

ASYS

BARK

BLBD

BSBR

CENT

CENTA

CNMD

CNXN

COHR

CPAY

CSGS

DGII

DLHC

ENSG

EQNR

EZPW

FORM

GEOS

HOLX

ITUB

KMPR

LFVN

LSAK

LUCK

LVWR

MTRX

NOTV

NTGR

NVST

NWSA

PAHC

Earnings Scheduled For February 5, 2025

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 10 years by 6.19% on an annualized basis producing an average annual return of 17.58%. Currently, Cencora has a market capitalization of $49.72 billion. 
Buying $100 In COR: If an investor had bought $100 of COR stock 10 years ago, it would be worth $510.85 today based on a price of $256.50 for COR at the time of writing.
<h3>Cencora's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738180811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Cencora 10 Years Ago Would Be Worth This Much Today

Wells Fargo analyst Eric Luebchow maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Equal-Weight and raises the price target from $237 to $251.

Wells Fargo Maintains Equal-Weight on Cencora, Raises Price Target to $251

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Cencora and provided 12-month price targets. The average target is $281.67, accompanied by a high estimate of $301.00 and a low estimate of $237.00. This current average has increased by 4.78% from the previous average price target of $268.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1737741658_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Cencora. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$301.00</td>
<td>$289.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$237.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$292.00</td>
<td>$287.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$285.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$263.00</td>
</tr>
<tr>
<td>John Belton</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$285.00</td>
<td>$250.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cencora. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cencora compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Cencora's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Cencora's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cencora analyst ratings.</a>
<h2>About Cencora</h2>
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
<h3>Key Indicators: Cencora's Financial Health</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Cencora's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.69% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Cencora's net margin is impressive, surpassing industry averages. With a net margin of 0.0%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.43%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Cencora's ROA excels beyond industry benchmarks, reaching 0.01%. This signifies efficient management of assets and strong financial health.
Debt Management: Cencora's debt-to-equity ratio stands notably higher than the industry average, reaching 6.79. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Cencora: 6 Analysts Share Their Views

Press Releases

Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results

Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035

Cencora Closes $1.8 Billion Senior Notes Offering

Cencora Completes Acquisition of Retina Consultants of America

Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release

Harrow Partners with Cencora to Launch "Harrow Cares" Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Cencora Reports Fiscal 2025 First Quarter Results

Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

Comments

Cencora

뉴스

파트너 / 기고자

벤징가 글로벌